You are here » Home » Companies » Company Overview » Divis Laboratories Ltd

Divis Laboratories Ltd.

BSE: 532488 Sector: Health care
NSE: DIVISLAB ISIN Code: INE361B01024
BSE LIVE 15:58 | 18 Aug 634.10 -11.40
(-1.77%)
OPEN

645.00

HIGH

645.00

LOW

631.60

NSE 15:59 | 18 Aug 635.20 -10.50
(-1.63%)
OPEN

640.00

HIGH

644.75

LOW

630.50

OPEN 645.00
PREVIOUS CLOSE 645.50
VOLUME 43976
52-Week high 1380.00
52-Week low 533.10
P/E 18.14
Mkt Cap.(Rs cr) 16,832
Buy Price 634.10
Buy Qty 446.00
Sell Price 0.00
Sell Qty 0.00
OPEN 645.00
CLOSE 645.50
VOLUME 43976
52-Week high 1380.00
52-Week low 533.10
P/E 18.14
Mkt Cap.(Rs cr) 16,832
Buy Price 634.10
Buy Qty 446.00
Sell Price 0.00
Sell Qty 0.00

Divis Laboratories Ltd. (DIVISLAB) - Company History

Divi's Laboratories Ltd is an India based manufacturer of Active Pharmaceutical Ingredients (APIs) and Intermediates. The company is engaged in manufacture of generic APIs custom synthesis of active ingredients and other specialty chemicals such as peptides and nutraceuticals. The company has three multi-purpose manufacturing facilities with a total reactor capacity of 4500 cubic meter and all support infrastructures such as Utilities environment management and safety systems. The company's main manufacturing and research and development facilities are located in the State of Andhra Pradesh India. The company has two subsidiaries: Divis Laboratories (USA) Inc and Divi's Laboratories Europe AG after marketing of Neutraceutical products in North American and European Countries.Divi's Laboratories Ltd was established in the year 1990 as Divis Research Center (DRC) with Research & Development as their prime fundamental. During the year 1991-93 the company successfully developed several commercial processes for intermediates and bulk actives and supplies to manufacturing majors. In the year 1994 they changed their name to Divis Laboratories Ltd to reflect their growing area of operations.In the year 1995 the company started operations in their manufacturing facility (Unit I) at Choutuppal near Hyderabad. In the year 1997 the company was certified as ISO-9002 compliant by SGS-Yarsley of U.K. In the year 1999 European Directorate gave a Certificate of Suitability (CoS) for Naproxen produced by the company. In the year 2001 the company received OHSAS-18001 Certification from BVQI of London for their Occupational Health and Safety Management Systems.In the year 2002 the company commenced setting up of their second manufacturing facility (Unit II) at Chippada near Visakhapatnam. In the year 2003 they opened a new research center christened DRC-Vizag for fundamental research in selected niche business core segments. The company went for initial public offering (IPO) and their shares were listed on Bombay Stock Exchange and National Stock Exchange.In the year 2004 the company invested an amount of Rs 3035.21 lakh towards capital expenditure at their manufacturing facilities at Choutuppal (Unit-I) and Chippada (Unit-II) for additional machinery installed at both Unit-I and Unit-II. In the year 2006 the company received letter of approval from Ministry of Commerce Government of India for setting up a sector-specific special economic zone (SEZ) for pharmaceutical ingredients at Chippada Bheemunipatnam in Visakhapatnam with investment of Rs 200 crore. The company's second manufacturing site at Chippada was converted into Export Oriented Unit (EOU) and started operations as EOU from June 1 2006.During the year 2006-07 the company developed an SEZ titled Divi's Pharma SEZ on a 250-acre site at Chippada Visakhapatnam. During the year 2007-08 the company set up new production as well as utility facilities in SEZ and EOU Units and enhanced existing capacities at Unit-1. They commissioned Nutraceuticals Manufacturing facility at Divi's Pharma SEZ and commenced commercial operations effective June 1 2008.During the year 2008-09 the company added 9 products to their product portfolio of which 4 are generic APIs and intermediates and 5 are custom synthesis APIs and intermediates. During the year 2009-10 they added 7 products to their product portfolio of which 2 are generic APIs and intermediates and 5 are custom synthesis APIs and intermediates.During the year 2010-11 the company added 21 products to their product portfolio of which 8 are generic APIs and intermediates and 13 are custom synthesis APIs and intermediates. The company set up a new facility called DSN SEZ Unit at Chippada in Visakhapatnam at an estimated cost of Rs 200 crore for creating additional capacities for the new opportunities in generic as well as custom synthesis segment. The DSN SEZ Unit commenced commercial operations from June 1 2011.